The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
) and the placebo group. Secondary endpoints, including LV ejection fraction, global longitudinal strain and N-terminal pro B-type natriuretic peptide, were also not significantly different between the CDR132L and placebo groups. Prespecified exploratory analyses suggested potential benefits of CDR132L treatment in patients with advanced adverse remodeling at baseline, supporting further evaluation of CDR132L, including in chronic heart failure conditions. ClinicalTrials.gov: NCT05350969 .
Authors
- Isabel Antorrena‐Miranda (ORCID: https://orcid.org/0000-0001-9523-3787)
- Orly Vardeny (ORCID: https://orcid.org/0000-0002-6387-1351)
- Wilfried Hauke
- Rebecca Altschul
- Kasper Vinther (ORCID: https://orcid.org/0000-0003-2424-2402)
- Michael Gamborg
- S D Anker
- P P Piotr Ponikowski
- G Filippatos
- T Thum
- Scott D. Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Tim Friede (ORCID: https://orcid.org/0000-0001-5347-7441)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Johann Bauersachs (ORCID: https://orcid.org/0000-0002-9341-117X)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Novo Nordisk (Denmark) (DK)
- National and Kapodistrian University of Athens (GR)
- Medizinische Hochschule Hannover (DE)
- Wroclaw Medical University (PL)
- Hospital La Paz Institute for Health Research (ES)
- German Centre for Cardiovascular Research (DE)
- University of Minnesota Medical Center (US)
- Novo Nordisk (Germany) (DE)
- Hannover Re (Germany) (DE)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-05-10
- DOI
- https://doi.org/10.1038/s41591-026-04408-4
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk